Top

Published in:

01-04-2015 | Original Article

Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents

Authors: Katharina Mahal, Sebastian Schruefer, Gustav Steinemann, Franziska Rausch, Rainer Schobert, Bernhard Biersack, Michael Höpfner

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2015

Abstract

Purpose

New (4-aryl-1-methylimidazol-5-yl)cinnamoylhydroxamic acids were prepared as potential dual mode anticancer agents combining the antivascular effect of the 4,5-diarylimidazole moiety and the histone deacetylases (HDAC) inhibition by the cinnamoyl hydroxamate.

Methods

Their antiproliferative activity against a panel of primary cells and cancer cell lines was determined by MTT assays and their apoptosis induction by caspase-3 activation. Their ability to reduce the activity of HDAC was measured by enzymatic assays and Western blot analyses of cellular HDAC substrates. Additional effects on cancer cell migration were ascertained via immunofluorescence staining of cytoskeleton components and three-dimensional migration assays. The chorioallantoic membrane assay was used as an in vivo model to assess their antiangiogenic properties.

Results

The 4-phenyl- and 4-(p-methoxyphenyl)-imidazole derivatives had a greater antiproliferative and apoptosis inducing effect in a variety of cancer cell lines when compared with the approved HDAC inhibitor SAHA, and most distinctly so in non-malignant human umbilical vein endothelial cells. Like SAHA, both compounds acted as pan-HDAC inhibitors. In 518A2 melanoma cells, they led to hyperacetylation of histones and of the cytoplasmic HDAC6 substrate alpha-tubulin. As a consequence, they inhibited the migration and invasion of these cells in transwell invasion assays. In keeping with its pronounced impact on endothelial cells, the 4-phenyl-imidazole derivative also inhibited the growth and sprouting of blood vessels in the chorioallantoic membrane of fertilized hen eggs.

Conclusions

The 4-phenyl- and 4-(p-methoxyphenyl)-imidazole compounds combine the antivascular effects of 4,5-diarylimidazoles with HDAC inhibition by cinnamoyl hydroxamates and show additional antimetastatic activity. They are promising candidates for pleiotropic HDAC inhibitors.

Available only for authorised users

Nebbioso A, Carafa V, Benedetti R, Altucci L (2012) Trials with “epigenetic” drugs: an update. Mol Oncol 6:657–682. doi:10.1016/j.molonc.2012.09.004 CrossRefPubMed

New M, Olzscha H, La Thangue NB (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6:637–656. doi:10.1016/j.molonc.2012.09.003 CrossRefPubMed

Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420–5432. doi:10.1038/sj.onc.1210610 CrossRefPubMed

Aldana-Masangkay GI, Sakamoto KM (2011) The role of HDAC6 in cancer. J Biomed Biotechnol 2011:1–10. doi:10.1155/2011/875824 CrossRef

Vidali G, Boffa LC, Bradbury EM, Allfrey VG (1978) Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci 75:2239–2243CrossRefPubMedCentralPubMed

Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51. doi:10.1038/nrc1779 CrossRefPubMed

Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51:1505–1529. doi:10.1021/jm7011408 CrossRefPubMed

Mai A, Altucci L (2009) Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 41:199–213. doi:10.1016/j.biocel.2008.08.020 CrossRefPubMed

Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981–989. doi:10.1158/1541-7786.MCR-07-0324 CrossRefPubMed

10.

Richon VM, Emiliani S, Verdin E et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci 95:3003–3007CrossRefPubMedCentralPubMed

11.

Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351–1356. doi:10.1038/sj.onc.1210204 CrossRefPubMed

12.

Maiso P, Carvajal-Vergara X, Ocio EM et al (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781–5789CrossRefPubMed

13.

Plumb JA, Finn PW, Williams RJ et al (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721–728PubMed

14.

Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280:145–153. doi:10.1016/j.canlet.2008.11.012 CrossRefPubMedCentralPubMed

15.

Kim H-J, Bae S-C (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3:166PubMedCentralPubMed

16.

Qian DZ (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12:634–642. doi:10.1158/1078-0432.CCR-05-1132 CrossRefPubMed

17.

Fantin VR, Richon VM (2007) Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 13:7237–7242. doi:10.1158/1078-0432.CCR-07-2114 CrossRefPubMed

18.

Wang J, Pursell NW, Samson MES et al (2013) Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther 12:925–936. doi:10.1158/1535-7163.MCT-12-1045 CrossRefPubMed

19.

Mahboobi S, Dove S, Sellmer A et al (2009) Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ, and histone deacetylases. J Med Chem 52:2265–2279. doi:10.1021/jm800988r CrossRefPubMed

20.

Gryder BE, Rood MK, Johnson KA et al (2013) Histone deacetylase inhibitors equipped with estrogen receptor modulation activity. J Med Chem 56:5782–5796. doi:10.1021/jm400467w CrossRefPubMed

21.

Guerrant W, Patil V, Canzoneri JC et al (2013) Dual-acting histone deacetylase-topoisomerase I inhibitors. Bioorg Med Chem Lett 23:3283–3287. doi:10.1016/j.bmcl.2013.03.108 CrossRefPubMedCentralPubMed

22.

Biersack B, Effenberger K, Schobert R, Ocker M (2010) Oxazole-bridged combretastatin a analogues with improved anticancer properties. ChemMedChem 5:420–427. doi:10.1002/cmdc.200900477 CrossRefPubMed

23.

Schobert R, Biersack B, Dietrich A et al (2010) 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin a resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J Med Chem 53:6595–6602. doi:10.1021/jm100345r CrossRefPubMed

24.

Di Fazio P, Lingelbach S, Schobert R, Biersack B (2014) 4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents. Invest New Drugs. doi:10.1007/s10637-014-0188-0 PubMed

25.

Shimada Y, Imamura M, Wagata T et al (1992) Characterization of 21 newly established esophageal cancer cell lines. Cancer 69:277–284CrossRefPubMed

26.

Sutter AP, Höpfner M, Huether A et al (2006) Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer. Int J Cancer 118:1814–1822. doi:10.1002/ijc.21512 CrossRefPubMed

27.

Evers BM, Ishizuka J, Townsend CM, Thompson JC (1994) The human carcinoid cell line, BON: a model system for the study of carcinoid tumors. Ann N Y Acad Sci 733:393–406. doi:10.1111/j.1749-6632.1994.tb17289.x CrossRefPubMed

28.

Gloesenkamp CR, Nitzsche B, Ocker M et al (2011) AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int J Oncol 40:876–888. doi:10.3892/ijo.2011.1256 PubMed

29.

Gloesenkamp C, Nitzsche B, Lim AR et al (2012) Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol 40:1659–1667. doi:10.3892/ijo.2012.1328 PubMed

30.

Hofmann UB, Houben R, Bröcker E-B, Becker JC (2005) Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87:307–314. doi:10.1016/j.biochi.2005.01.013 CrossRefPubMed

31.

Boyden S (1962) The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115:453–466CrossRefPubMedCentralPubMed

32.

Entschladen F, Drell TL, Lang K et al (2005) Analysis methods of human cell migration. Exp Cell Res 307:418–426. doi:10.1016/j.yexcr.2005.03.029 CrossRefPubMed

33.

Albini A, Iwamoto Y, Kleinman HK et al (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239–3245PubMed

34.

Nitzsche B, Gloesenkamp C, Schrader M et al (2010) Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer 103:18–28. doi:10.1038/sj.bjc.6605725 CrossRefPubMedCentralPubMed

35.

Baradari V, Huether A, Hopfner M et al (2006) Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 13:1237–1250. doi:10.1677/erc.1.01249 CrossRefPubMed

36.

Kim MS, Yamashita K, Baek JH et al (2006) N-methyl-d-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66:3409–3418CrossRefPubMed

37.

Zhang Y, Li N, Caron C et al (2003) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22:1168–1179CrossRefPubMedCentralPubMed

38.

Hubbert C, Guardiola A, Shao R et al (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455–458. doi:10.1038/417455a CrossRefPubMed

39.

Matsuyama A, Shimazu T, Sumida Y et al (2002) In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21:6820–6831CrossRefPubMedCentralPubMed

40.

Sadoul K, Wang J, Diagouraga B, Khochbin S (2011) The tale of protein lysine acetylation in the cytoplasm. J Biomed Biotechnol 2011:1–15. doi:10.1155/2011/970382 CrossRef

41.

Kim SC, Sprung R, Chen Y et al (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23:607–618. doi:10.1016/j.molcel.2006.06.026 CrossRefPubMed

42.

Zhang X, Yuan Z, Zhang Y et al (2007) HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27:197–213. doi:10.1016/j.molcel.2007.05.033 CrossRefPubMedCentralPubMed

43.

Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362–374. doi:10.1038/nrc1075 CrossRefPubMed

44.

Deroanne CF, Bonjean C, Servotte S et al (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427–436CrossRefPubMed

45.

Jeong J-W, Bae M-K, Ahn M-Y et al (2002) Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111:709–720CrossRefPubMed

Title: Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents
Authors: Katharina Mahal
Sebastian Schruefer
Gustav Steinemann
Franziska Rausch
Rainer Schobert
Bernhard Biersack
Michael Höpfner
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2685-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody

Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer

Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy

Stabilization of the Karenitecin ® lactone by alpha-1 acid glycoprotein

Synthesis and biological evaluation of geldanamycin analogs against human cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer